Home Tags HydraSpace

Tag: HydraSpace

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...

New ADC Payload Platform – Synaffix Launches toxSYN™

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology

The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...

Synaffix Receives Key Patent for its HydraSpace™ Spacer Technology

Earlier today, Synaffix, a Netherlands based biotechnology company focusing on the development of industry-leading antibody-drug conjugate technology platforms, confirmed receiving a key patent covering...

Synaffix ADCs Significantly Expands the Therapeutic Index vs Cysteine-Engineered ADCs

Netherlands-bases biotechnology company Synaffix BV, which exclusively focuses on the development of novel antibody-drug conjugate (ADC) technology,  confirmed that a new set of head-to-head...

New Key Patent Covers Synaffix’s Glycan-Conjugated ADC Development Process

Synaffix, a Netherlands-based biotechnology company exclusively focused on the continued advancement of best-in-class ADC technology platforms has received a new key patent for their...

Synaffix and ADC Therapeutics Sign Agreement for GlycoConnect™ and HydraSpace™ Technologies

Netherlands-based biotechnology company Synaffix has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary site-specific antibody-drug conjugate technologies. The company is exclusively focused...

Preclinical Studies Show Significant Improved Therapeutic Index

Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...

Synaffix’s New High Potency Lab now Fully Operational to Support Growing...

Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...

Novel Proprietary Linkers Enable Challenging Hydrophobic Payloads to be Efficiently Conjugated...

The introduction of two recently FDA-approved antibody-drug conjugates (ADCs) Brentuximab vedotin (Adcetris™; Seattle Genetics), an antibody-drug conjugate (ADC) or immunoconjugate directed to CD30 which...